Harbour BioMed Launches Fully Human Generative AI HCAb Model

October 29, 2025
Harbour BioMed has introduced its first fully human Generative AI HCAb Model, designed to accelerate biologics discovery through AI-driven antibody generation and validation, as announced in a press release.

Harbour BioMed has launched its first fully human Generative AI HCAb (Heavy Chain-Only Antibody) Model powered by its Hu-mAtrIx AI platform, announced in a press release. The model was unveiled during the company’s Global R&D Day 2025 event in Shanghai.

The AI HCAb Model integrates sequence generation, intelligent screening, and wet-lab validation into a closed-loop workflow. Trained on nine million HCAb sequences and public data, it uses a fine-tuned protein language model to design and optimize antibody sequences. Candidates that meet stability and developability criteria are synthesized and validated experimentally.

According to the company, the model achieved a tenfold increase in candidate generation and a 78.5% success rate in target binding. Twenty molecules underwent additional laboratory validation, showing high activity, purity, and yield, with nanomolar-level binding affinities.

Harbour BioMed also announced the formation of the Global AI + Pharmaceutical Ecosystem Alliance at the same event. The alliance includes industry partners such as Insilico Medicine, Evinova, and Deep Intelligent Pharma, aiming to advance AI-driven drug discovery and development.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Life Sciences

10/29
ExaCare AI Raises $30M Series A to Expand AI Platform for Skilled Nursing Facilities
10/29
MCG Health and Allegheny Health Network to Present on AI in Utilization Management at ACMA 2025
10/29
CareSet Names Sepideh Naseri Chief Data and Analytics Officer
10/29
ID.me and Flexpa Partner to Strengthen Health Data Access and Security
10/29
Tellihealth Names Chuck Washburn as Chief Revenue Officer

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Industry analysis

2025 Global Business Services Agenda: Gen AI Takes Center Stage

The Hackett Group

This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.

Read more

You May Also Like